Information Provided By: 
Fly News Breaks for November 17, 2015
KIN
Nov 17, 2015 | 08:31 EDT
As noted earlier, BMO Capital downgraded Kindred Biosciences to Market Perform from Outperform. After the pivotal field study of company's SentiKind, for post-operative pain in dogs, did not meet its primary endpoint, BMO Capital downgraded the stock based on concerns about the company's execution and low expectations for the rest of the company's pipeline. Target to $5 from $14.
News For KIN From the Last 2 Days
There are no results for your query KIN
